Non-steroidal progesterone receptor modulators

Compounds of the general formula I

• in which
• A is hydrogen, a C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl radical which is optionally mono- or polysubstituted identically or differently by Z, or a C3-C10-cycloalkyl or 3-12-membered heterocycloalkyl radical which is optionally mono- or polysubstituted identically or differently by M, or else is Z itself, where Z is defined as follows:
• cyano, halogen, hydroxyl, nitro, —C(O)Rb, CO2Rb, —O—Rb, —S—Rb, SO2NRcRd, —C(O)—NRcRd, —OC(O)—NRcRd, C═NORb, —NRcRd, —PO3(Rb)2, —NReCORb, —NReCSRb, —NReS(O)Rb, —NReS(O)2Rb, —NReCONRcRd, —NReCOORb, —NReC(NH)NRcRd, —NReCSNRcRd, —NReS(O)NRcRd, —NReS(O)2NRcRd, —S(O)R , —S(O)NRcRd, —S(O)2Rb, —SO2ORb, —CSNRcRd, —CRb(OH)—Rb or
• a C3-C10-cycloalkyl or 3-12-membered heterocycloalkyl radical which is optionally mono- or polysubstituted identically or differently by M and
• M is C1-C6-alkyl or a —CORb, CO2Rb, —O—Rb or —NRcRd group, where
• Rb is hydrogen or a C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C10-cycloalkyl, C6-C12-aryl or a partly or fully fluorinated C1-C3-alkyl radical and
• Rc and Rd are each independently hydrogen, a C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C10-cycloalkyl, C6-C12-aryl radical;
• a C(O)Rb group where Rb is as defined above or a hydroxyl group,
• where, when
• Rc is a hydroxyl group, Rd can only be hydrogen, C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C10-cycloalkyl or C6-C12-aryl, and vice versa, and also
• Re is hydrogen, C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C10-cycloalkyl or C6-C12-aryl, and
• R1 and R2 are each independently an unbranched or branched C1-C5-alkyl group or, together with the carbon atom of the chain, form a ring having a total of 3-7 members,
• where, when
• A is hydrogen, R1 and R2 cannot both be a methyl radical,
• R3 is hydrogen or a C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C10-cycloalkyl, 3-12-membered heterocycloalkyl radical which is optionally mono- or polysubstituted identically or differently by K, or a mono- or bicyclic C6-C12-aryl or 3-12-membered heteroaryl radical which is optionally mono- or polysubstituted identically or differently by L, and
• K is cyano, halogen, hydroxyl, nitro, —C(O)Rb, CO2Rb, —O—Rb, —S—Rb, SO2NRcRd, —C(O)—NRcRd, —OC(O)—N RcRd, —C═NORb, —NRcRd or a C3-C10-cycloalkyl, 3-12-membered heterocycloalkyl radical which is optionally mono- or polysubstituted identically or differently by M, or a C6-C12-aryl or 3-12-membered heteroaryl radical which is optionally mono- or polysubstituted by L, with the definition of M specified under A, and
• L is C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, a partly or fully fluorinated C1-C6-alkyl, a partly or fully fluorinated C1-C6-alkoxy, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkoxy, a mono- or bicyclic (CH2)p—C3-C10-cycloalkyl, a mono- or bicyclic 3-12-membered (CH2)p-heterocycloalkyl radical, (CH2)pCN, (CH2)pHal, (CH2)pNO2, a mono- or bicyclic (CH2)p—C6-C12-aryl radical, a mono- or bicyclic 3-12-membered (CH2)p-heteroaryl radical, or
• —(CH2)pPO3(Rb)2, —(CH2)pNRcRd, —(CH2)pNReCORb, —(CH2)pNReCSRb, —(CH2)pNReS(O)Rb, —(CH2)pNReS(O)2Rb, —(CH2)pNReCONRcRd, —(CH2)pNReCOORb, —(CH2)pNReC(NH)NRcRd, —(CH2)pNReCSNRcRd, —(CH2)pNReS(O)NRcRd, —(CH2)pNReS(O)2NRcRd, —(CH2)pCOR , —(CH2)pCSR , —(CH2)p S(O)Rb, —(CH2)pS(O)(NH)Rb, —(CH2)pS(O)2Rb, —(CH2)pS(O)2NRcRd, —(CH2)pSO2ORb , —(CH2)pCO2Rb, —(CH2)pCONRcRd, —(CH2)pCSNRcRd, —(CH2)pORb, —(CH2)pSRb, —(CH2)pCRb(OH)—Rb, —(CH2)p—C═NORb, —O—(CH2)n—O—, —O—(CH2)n—CH2—, —O—CH═CH— or —(CH2)n+2-
• and the terminal oxygen atoms and/or carbon atoms are linked to directly adjacent ring carbon atoms and
• n is 1 or 2 and
• p is 0, 1, 2, 3, 4, 5 or 6, and
• X is one oxygen atom and two hydrogen atoms
• Y is (CH2)m, —C≡C— or —CH═CH— where
• m=0 or 1, and
• R4 is an aromatic or heteroaromatic 3- to 12-membered mono- or bicycle which is unsubstituted or optionally substituted by from 1 to 3 of the radicals mentioned under L, or one of the following groups mentioned under B or C:
• B:
• 6-membered/6-membered ring systems:
• C:
• 6-membered/5-membered ring systems:
• where
• R5 is hydrogen or C1-C4-alkyl, or a partly or fully fluorinated C1-C4-alkyl,
• R6a and R6b are each independently hydrogen, C1-C4-alkyl or a partly or fully fluorinated C1-C4-alkyl, or, together with the ring carbon atom, form a 3- to 6-membered ring,
• and the pharmaceutically acceptable salts thereof.